vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $13.8M, roughly 1.3× CB Financial Services, Inc.). On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 19.9%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 1.2%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CBFV vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $18.6M |
| Net Profit | — | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 38.1% | 56.3% |
| Net Margin | — | 65.7% |
| Revenue YoY | 19.9% | 1808.5% |
| Net Profit YoY | — | 376.5% |
| EPS (diluted) | $0.90 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $18.6M | ||
| Q3 25 | $2.4M | $334.0K | ||
| Q2 25 | $13.5M | $1.4M | ||
| Q1 25 | $12.1M | $257.0K | ||
| Q4 24 | $13.2M | $977.0K | ||
| Q3 24 | $12.7M | $660.0K | ||
| Q2 24 | $12.2M | $736.0K | ||
| Q1 24 | $13.5M | $1.4M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | $-5.7M | $-8.6M | ||
| Q2 25 | $3.9M | $-6.9M | ||
| Q1 25 | $1.9M | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.2M | $-2.8M | ||
| Q2 24 | $2.6M | $-14.5M | ||
| Q1 24 | $4.2M | $411.0K |
| Q4 25 | 38.1% | 56.3% | ||
| Q3 25 | -289.8% | -2516.5% | ||
| Q2 25 | 35.0% | -701.0% | ||
| Q1 25 | 19.3% | -3350.2% | ||
| Q4 24 | 23.1% | — | ||
| Q3 24 | 31.2% | -1563.6% | ||
| Q2 24 | 26.4% | -1255.0% | ||
| Q1 24 | 37.9% | -692.5% |
| Q4 25 | — | 65.7% | ||
| Q3 25 | -235.2% | -2572.2% | ||
| Q2 25 | 29.3% | -504.8% | ||
| Q1 25 | 15.8% | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.3% | -425.5% | ||
| Q2 24 | 21.8% | -1964.4% | ||
| Q1 24 | 31.1% | 29.9% |
| Q4 25 | $0.90 | $0.25 | ||
| Q3 25 | $-1.07 | $-0.17 | ||
| Q2 25 | $0.74 | $-0.14 | ||
| Q1 25 | $0.35 | $-0.11 | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.60 | $-0.06 | ||
| Q2 24 | $0.51 | $-0.30 | ||
| Q1 24 | $0.82 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $157.5M | $49.4M |
| Total Assets | $1.5B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $40.0M | ||
| Q3 25 | $55.9M | $37.9M | ||
| Q2 25 | $64.5M | $44.8M | ||
| Q1 25 | $61.3M | $40.6M | ||
| Q4 24 | $49.6M | $59.3M | ||
| Q3 24 | $147.3M | $68.8M | ||
| Q2 24 | $142.6M | $73.0M | ||
| Q1 24 | $73.7M | $80.2M |
| Q4 25 | $157.5M | $49.4M | ||
| Q3 25 | $152.5M | $36.4M | ||
| Q2 25 | $148.4M | $44.5M | ||
| Q1 25 | $148.3M | $50.5M | ||
| Q4 24 | $147.4M | $55.1M | ||
| Q3 24 | $149.1M | $58.5M | ||
| Q2 24 | $142.9M | $60.4M | ||
| Q1 24 | $141.6M | $74.1M |
| Q4 25 | $1.5B | $59.0M | ||
| Q3 25 | $1.5B | $51.1M | ||
| Q2 25 | $1.5B | $60.7M | ||
| Q1 25 | $1.5B | $67.9M | ||
| Q4 24 | $1.5B | $90.6M | ||
| Q3 24 | $1.6B | $99.0M | ||
| Q2 24 | $1.6B | $107.8M | ||
| Q1 24 | $1.5B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $18.4M |
| Free Cash FlowOCF − Capex | $17.2M | — |
| FCF MarginFCF / Revenue | 124.1% | — |
| Capex IntensityCapex / Revenue | 4.7% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $18.4M | ||
| Q3 25 | $4.6M | $-8.7M | ||
| Q2 25 | $4.1M | $-7.5M | ||
| Q1 25 | $4.0M | $-7.5M | ||
| Q4 24 | $6.8M | $-24.0M | ||
| Q3 24 | $3.1M | $765.0K | ||
| Q2 24 | $-1.2M | $-10.9M | ||
| Q1 24 | $3.3M | $-4.0M |
| Q4 25 | $17.2M | — | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $3.9M | — | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $-2.4M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | 124.1% | — | ||
| Q3 25 | 186.5% | — | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 32.5% | — | ||
| Q4 24 | 26.0% | — | ||
| Q3 24 | 17.4% | — | ||
| Q2 24 | -19.6% | — | ||
| Q1 24 | 17.0% | — |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 25.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 10.0% | — | ||
| Q1 24 | 7.2% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
